![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 2-Apr-2013[ | E-mail |
Share ] Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
(Boston) The Joanna M. Nicolay Melanoma Foundation (JMNMF) presented Elizabeth Shenk, a student in both the Boston University Biomedical Engineering Department and the Boston University School of Medicine (BUSM) Pharmacology Training Program with one of ten, nationally competitive, 2013 "Research Scholar Awards" (RSA). The $10,000 grants support exceptional graduate student melanoma research and also provide distinction to lab directors, universities and cancer research institutions across the U.S.
The JMNMF is the first program in the U.S. to fund graduate student melanoma researchers. The Research Scholar Award program was initially piloted with the Johns Hopkins Sidney Kimmel Cancer Center in 2006, and expanded nationally to benefit the broader academic, scientific, clinical and patient communities and encourage larger numbers of students to choose melanoma research as their professional career path. To date 146 students and 47 cancer research centers are distinguished through their active involvement in this nationally-renowned program.
Shenk graduated with honors and high distinction from Penn State in May 2010 and subsequently enrolled in the two Boston University PhD programs. She works under Rhoda Alani, MD, BUSM's Herbert Mescon Chair of Dermatology, and collaborates with Joyce Wong, PhD, and Mario Cabodi, PhD, both of BU's College of Engineering Biomedical Engineering department.
Shenk's research aims to determine which tumors, specifically melanomas, are likely to metastasize using a three dimensional engineered platform. She has been instrumental in creating the cellular model of this system, which is expected to be used to develop novel therapies targeting the metastatic progress on an individualized basis for patients at risk for metastasis.
According to Regina Shannon Bodnar, JMNMF Chair, "Our Foundation's 'Research Scholar Awards' are invaluable at the grassroots level, to specifically grow interest in melanoma research, at leading cancer research centers nationwide. If we can attract the brightest young minds, that are considering or are already within the nation's cancer research pipelines, to pursue a career in melanoma research we're that much closer to better understanding the disease, identifying the means for effective treatments and, most importantly, finding a cure for this deadly and increasingly prevalent disease."
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 2-Apr-2013[ | E-mail |
Share ] Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
(Boston) The Joanna M. Nicolay Melanoma Foundation (JMNMF) presented Elizabeth Shenk, a student in both the Boston University Biomedical Engineering Department and the Boston University School of Medicine (BUSM) Pharmacology Training Program with one of ten, nationally competitive, 2013 "Research Scholar Awards" (RSA). The $10,000 grants support exceptional graduate student melanoma research and also provide distinction to lab directors, universities and cancer research institutions across the U.S.
The JMNMF is the first program in the U.S. to fund graduate student melanoma researchers. The Research Scholar Award program was initially piloted with the Johns Hopkins Sidney Kimmel Cancer Center in 2006, and expanded nationally to benefit the broader academic, scientific, clinical and patient communities and encourage larger numbers of students to choose melanoma research as their professional career path. To date 146 students and 47 cancer research centers are distinguished through their active involvement in this nationally-renowned program.
Shenk graduated with honors and high distinction from Penn State in May 2010 and subsequently enrolled in the two Boston University PhD programs. She works under Rhoda Alani, MD, BUSM's Herbert Mescon Chair of Dermatology, and collaborates with Joyce Wong, PhD, and Mario Cabodi, PhD, both of BU's College of Engineering Biomedical Engineering department.
Shenk's research aims to determine which tumors, specifically melanomas, are likely to metastasize using a three dimensional engineered platform. She has been instrumental in creating the cellular model of this system, which is expected to be used to develop novel therapies targeting the metastatic progress on an individualized basis for patients at risk for metastasis.
According to Regina Shannon Bodnar, JMNMF Chair, "Our Foundation's 'Research Scholar Awards' are invaluable at the grassroots level, to specifically grow interest in melanoma research, at leading cancer research centers nationwide. If we can attract the brightest young minds, that are considering or are already within the nation's cancer research pipelines, to pursue a career in melanoma research we're that much closer to better understanding the disease, identifying the means for effective treatments and, most importantly, finding a cure for this deadly and increasingly prevalent disease."
###
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-04/bumc-bsr040213.php
mayweather vs cotto shumpert hopkins hopkins dear john derrick rose torn acl pacers
UPDATE: A spokesman from Zalora Taiwan said: To better serve Taiwan on its business operations model, the company has decided to conduct a review to make changes ? From April, we are shifting part of Taiwan?s operations to our regional headquarters in Singapore. During this migration period, our company will temporarily disable operations of the Taiwanese site. We sincerely apologize for any inconvenience this may cause to our customers, and we promise that any returns and refunds will be processed as per the time period stipulated on our site. If you have any further queries, please contact CS@zalora.com.tw, our customer service department will answer your questions within one working day. ZALORA TAIWAN denies any rumours regarding bankruptcy or closure. We will process and complete all payments to our customers and vendors. All our employees will be managed in accordance with and with respect to the labour law in Taiwan. We will not make any further comment on rumours, and reserve the right to take legal action against any parties making false statements about us. One year after launching in Taiwan, Rocket Internet-backed Zalora may be shutting down its operations in the country. Though the Singapore-based fashion e-tailer has yet to issue a confirmation, e27 notes several signs that a closure of its Taiwan branch is already in progress. Zalora Taiwan’s Web site currently says that it will no longer provide telephone services for customer support after today. Furthermore, Taiwanese TV news station TVBS reported last week (link via Google Translate) that more than 100 employees were suddenly laid off as Zalora?canceled orders from suppliers.?Reasons cited by TVBS for Zalora Taiwan’s potential demise include the high cost of marketing in Taiwan’s saturated online retail market, which is already dominated by e-commerce sites Yahoo! Taiwan and PChome. Zalora recently landed several high-profile investments, including $26 million from German retail conglomerate Tengelmann Group, but as Jacky Yap of e27 notes, Rocket Internet has already encountered several setbacks in Southeast Asia, including the closure of Home24. “Rocket Internet will not hesitate to pull the plug when it comes to evaluating a likely failure,” just as it shut down its operations in Turkey last August, Yap writes. Despite Zalora’s rapid growth, the reported closure of its Taiwan operations is a reminder that Rocket Internet’s foothold on the Asian market is still not a sure thing. I’ve reached out to Zalora’s HQ for comment and will
